Relationship of Handgrip Strength and Body Mass Index With Cognitive Function in Patients With Schizophrenia

Shinsuke Hidese 1,2, Junko Matsuo 1, Ikki Ishida 1, Moeko Hiraishi 1, Toshiya Teraishi 1, Miho Ota 1, Kotaro Hattori 1 and Hiroshi Kunugi 1,2*

1 Department of Mental Disorder Research, National Center of Neurology and Psychiatry, National Institute of Neuroscience, Tokyo, Japan, 2 Division of Cognitive and Behavioral Medicine, Department of National Center of Neurology and Psychiatry Brain Physiology and Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

**Background:** The relationship between muscle strength and cognition in schizophrenia has not been well studied. We investigated the potential relationship of handgrip strength (HGS) score and body mass index (BMI) with cognitive function in patients with schizophrenia.

**Methods:** Participants included 153 patients with schizophrenia (age: 36.9 ± 9.4 years; 82 males) and 328 healthy controls (age: 36.4 ± 10.7 years; 150 males), matched for age, sex, and ethnicity (Japanese). HGS was measured using a digital handgrip dynamometer. Cognitive function was evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) test. A two-way multivariate analysis of covariance was used to compare HGS scores between the patient and control groups. Multiple regression analyses of BACS scores were performed in the patient and control groups using HGS and BMI scores as independent variables.

**Results:** In the intergroup comparison, significantly lower HGS scores were observed in patients with schizophrenia than in healthy controls (p < 0.05, corrected). In the patient group, there was a significantly positive correlation between HGS scores and BACS composite score (male, p = 0.0014; female, p = 0.0051). However, BMI scores were significantly negatively correlated with the BACS composite score (male, p = 0.0022; female, p = 0.018). Furthermore, the ratio of HGS/BMI was significantly positively correlated with the BACS composite score in the patient group (p = 0.00000018).

**Conclusions:** Cognitive function in patients with schizophrenia is correlated positively with HGS and negatively with BMI. HGS/BMI may thus be a good index for cognitive performance in schizophrenia.

**Keywords:** body mass index, cognitive function, handgrip strength, schizophrenia, physical activity

**Abbreviations:** ANCOVA, analysis of covariance; BACS, Brief Assessment of Cognition in Schizophrenia; BMI, body mass index; CPeq, chlorpromazine-equivalent; HGS, handgrip strength; MANCOVA, multivariate analysis of covariance; M.I.N.I., mini-international neuropsychiatric interview.
INTRODUCTION

Handgrip strength (HGS) is a concise measure used to evaluate muscle strength, and reference values have been published for healthy adults by age and sex [1, 2]. Lower HGS has been associated with sedentary lifestyle [3]. HGS is related to physical and cognitive abilities, particularly in elderly people. This relationship has been demonstrated in systematic reviews reporting that lower HGS is associated with increased risk of cognitive decline in elderly populations [4–7]. Patients with schizophrenia exhibit broad cognitive deficits in the early stages of the illness [8, 9], and physical exercise has been suggested to improve the deficits [10–13]. Light physical activity was positively correlated with cognitive performance [14], while moderate-to-vigorous physical activity was associated with greater cognitive disorganization symptoms in patients with schizophrenia [15]. Although studies regarding HGS remain scarce, lower HGS scores and exacerbated cognitive symptoms were observed in physically inactive patients with schizophrenia [16].

Body mass index (BMI) is a popular index for nutritional status [17] which has been negatively associated with moderate-to-vigorous physical activity [18]. Therefore, BMI may be associated with HGS, which is possibly attributed to physical activity levels. It has been documented that weight gain in schizophrenia can be facilitated by psychotropic medications and unhealthy lifestyle habits [19]. In line with these findings, patients with schizophrenia exhibited more sedentary behavior, which was associated with increased BMI and cognitive symptom scores [20]. In contrast, participation in sports has been demonstrated to reduce BMI and ameliorate psychiatric symptoms in patients with schizophrenia [21].

Obesity (the state of abnormally increased BMI score, BMI ≥ 27.5 kg/m²) has been reported to be associated with cognitive impairments in schizophrenia [22]. The MATRICS Consensus Cognitive Battery scores were correlated positively with aerobic fitness (an index of physical ability indicated by VO₂max) and negatively with increased BMI scores in patients with schizophrenia [23]. Moreover, BMI scores correlated with Eurofit test battery scores, which are assessments of health-related fitness, but not with the HGS subtest score, in patients with schizophrenia or schizoaffective disorder [24]. In addition, [16] reported no correlation between HGS score and cognitive symptoms in a non-elderly sample of patients with schizophrenia (n = 80) and healthy adult controls (n = 40).

Based on the reported associations between physical and cognitive abilities, it is of particular interest to examine the possible relationship between HGS and cognitive performance in patients with schizophrenia. We aimed to assess this relationship by using the Brief Assessment of Cognition in Schizophrenia (BACS) in a relatively large sample of patients with schizophrenia and healthy controls. It was hypothesized that there would be a positive correlation between HGS score and cognitive function.

MATERIALS AND METHODS

Participants

Participants comprised 153 patients with schizophrenia (mean ± standard deviation age: 36.9 ± 9.4 years, 82 males) and 328 healthy controls (36.4 ± 10.7 years, 150 males), matched for age, sex, and ethnicity (Japanese). To exclude the possible effect of aging, only those who were <60 years old were registered. All the participants were self-reported right-handers, and were enrolled through recruitment forms at the National Center of Neurology and Psychiatry, advertisements in free magazines, and our website announcement. The participants were screened for axis I psychiatric disorders by trained psychiatrists using the Japanese version of the Mini-International Neuropsychiatric Interview (M.I.N.I.) [25, 26]. The diagnosis was made in accordance with the Diagnostic and Statistical Manual of Mental Disorders–4th edition criteria [27] based on the information from M.I.N.I. and medical records, if available. All healthy controls were confirmed to have no axis I psychiatric disorders and to have never received psychiatric services. Patients and controls with a medical history of neurological diseases, severe head injury, substance abuse, or mental retardation were excluded. All participants signed consent forms after the study explanation. The study protocol was approved by the ethics committee at the National Center of Neurology and Psychiatry, and applied according to the Declaration of Helsinki [28].

Clinical and Psychological Assessments

HGS was measured using a digital handgrip dynamometer (T.K.K.5401; Takei Co., Tokyo, Japan). Right (dominant) and left (non-dominant) HGSs were calculated for each participant by taking the mean of two records conducted for each hand. The average HGS was then calculated for each participant by taking the mean of the two records conducted for each hand. The average HGS was then calculated for each participant by taking the mean of the dominant and non-dominant HGSs. The severity of symptoms in the patients was evaluated by trained psychiatrists using the Japanese adaptation of the Positive and Negative Syndrome Scale [29, 30]. Cognitive functions were evaluated by trained psychologists using the Japanese version of the BACS [31, 32]. The BACS composite score was the mean z score calculated from each BACS score, based on the mean and standard deviation of the healthy controls. Daily doses of antipsychotics were converted to chlorpromazine-equivalent (CPEq) doses according to published guidelines [33].

Statistical Analyses

Continuous and categorical variables were compared between the patient and control groups using Welch’s t- and chi-square tests, respectively. Correlations for continuous and categorical variables were calculated using Pearson’s and Spearman’s correlation coefficients, respectively. BACS scores were compared using a one-way (diagnostic) multivariate analysis of covariance (MANCOVA), controlling for age, sex, and BMI. HGS scores were compared using a two-way (diagnosis x sex) MANCOVA, controlling for age and BMI. Comparisons of average HGS among BMI-based classification groups (underweight: BMI < 18.5; normal: 18.5 ≤ BMI < 25, overweight: 25 ≤ BMI < 30, obese: BMI ≥ 30) [34] were conducted using analysis of
covariance (ANCOVA), controlling for age and sex. CPeq and any psychotropic medication use were accounted for in the patient group. Multiple regression analyses were performed using the BACS scores as dependent variables and applying independent variables by the forced-entry method. Bonferroni corrections for multiple testing were performed for all the group comparisons, correlations, and multiple regression analyses. For instance, as correlations and multiple regression analyses were repeated with regard to all seven BACS scores, the statistical significance level was set to \( p < 0.05/7 \). Effect sizes were calculated by Cohen’s \( d \) for the \( t \)-test, \( \phi \) for the chi-square test, \( \eta^2 \) for the ANCOVA and MANCOVA, and adjusted \( R^2 \) for the multiple regression analysis. Statistical analyses were conducted using the Statistical Package for the Social Sciences version 24.0 (SPSS Japan, Tokyo, Japan). All statistical tests were two-tailed, and a \( p \)-value of <0.05 was deemed significant.

**RESULTS**

**Analyses of Clinical Variables**

Demographic and clinical characteristics of the participants are depicted in Table 1. Mean BMI was significantly higher in patients with schizophrenia than in healthy controls after correction for multiple testing. With regard to BMI-based classification, the proportion of normal participants was significantly lower (odds ratio = 0.45, 95% confidence interval: 0.30–0.68), while that of obese participants was significantly higher in the patient group than in the control group (odds ratio = 4.52, 95% confidence interval: 2.00–10.40; corrected). A MANCOVA analysis revealed that all of the BACS scores were significantly lower in the patient group than in the control group (corrected).

**Analyses of HGS Scores**

HGS scores of the participants are depicted in Table 2. A two-way MANCOVA revealed that all HGS scores were significantly lower in the patient group than in the control group, and were significantly higher in males than in females (corrected). The average HGS (i.e., the average of left and right HGS scores) was used as “the HGS score” in the following analyses. Correlations between HGS score and clinical variables are demonstrated in Table S1. Of note, BMI was significantly positively correlated with HGS score in both groups (patient: \( r = 0.27, p = 8.0.E-04 \); control: \( r = 0.40, p = 3.4.E-14 \)). Comparisons of HGS scores by BMI-based classification are displayed in Figure S1.

**Correlation of HGS and BMI Scores With Cognitive Function**

Multiple regression analysis for each sex involving BACS scores and forced-entry variables are documented in Table 3. BACS scores were used as dependent variables, while HGS scores, age, BMI, education (years), CPeq (for patients), and any psychotropic medication use (for patients) were used as independent variables. Attention (\( \beta = 0.47, p = 4.0.E-05 \)) and composite (\( \beta = 0.36, p = 1.4.E-03 \)) scores were significantly positively correlated with HGS scores in male patients (corrected). Motor speed (\( \beta = 0.34, p = 1.5.E-03 \)), attention (\( \beta = 0.36, p = 1.4.E-03 \)), and composite (\( \beta = 0.30, p = 5.1.E-03 \)) scores were significantly positively correlated with HGS scores in female patients (corrected). Motor speed (\( \beta = -0.40, p = 1.3.E-03 \)) and composite (\( \beta = -0.36, p = 2.2.E-03 \)) scores were significantly negatively correlated with BMI in male patients (corrected). Working memory was significantly negatively correlated with BMI in female patients (\( \beta = -0.34, p = 6.9.E-03 \), corrected). No significant correlations were observed between the HGS and BACS scores in male or female controls. However, working memory (\( \beta = -0.21, p = 5.8.E-03 \)) and composite (\( \beta = -0.22, p = 2.8.E-03 \)) scores were significantly negatively correlated with BMI in female controls (corrected).

Based on these results, further multiple regression analysis was conducted using a newly-defined index, namely the ratio of HGS to BMI (Table 4). BACS scores were used as dependent variables, while HGS/BMI, age, sex, education (years), CPeq (for patients), and any psychotropic medication use (for patients), were used as independent variables. In this case, working memory (\( \beta = 0.35, p = 9.7.E-04 \)), motor speed (\( \beta = 0.47, p = 1.2.E-05 \)), verbal fluency (\( \beta = 0.40, p = 2.3.E-04 \)), attention (\( \beta = 0.56, p = 2.9.E-08 \)), and composite (\( \beta = 0.51, p = 1.8.E-07 \)) scores were significantly positively correlated with HGS/BMI in the patient group (corrected). Composite score was significantly positively correlated with HGS/BMI in the control group (\( \beta = 0.20, p = 2.6.E-03 \), corrected).

**Correlation Between Cognitive Function and Clinical Variables**

Correlations between the BACS scores and clinical variables are documented in Table S2. In bivariate correlation analyses, attention (\( r = 0.23, p = 3.5.E-03 \)) and composite (\( r = 0.25, p = 2.3.E-03 \)) scores were significantly positively correlated with HGS score in the patient group (corrected). Verbal memory (\( r = -0.26, p = 1.5.E-03 \)), working memory (\( r = -0.30, p = 2.2.E-04 \)), motor speed (\( r = -0.28, p = 6.1.E-04 \)), verbal fluency (\( r = -0.26, p = 1.1.E-03 \)), attention (\( r = -0.27, p = 7.8.E-04 \)), and composite (\( r = -0.33, p = 4.4.E-05 \)) scores were significantly negatively correlated with BMI in the patient group (corrected). Notably, all of the BACS scores were significantly positively correlated with HGS/BMI in the patient group (Figure 1, corrected). In the control group, BACS scores were not significantly correlated with HGS score. However, verbal memory (\( r = -0.24, p = 7.9.E-06 \)), working memory (\( r = -0.21, p = 1.6.E-04 \)), attention (\( r = -0.27, p = 5.5.E-07 \)), and composite (\( r = -0.28, p = 4.3.E-07 \)) scores were significantly negatively correlated with BMI in the control group (corrected). By contrast, only working memory score showed a significantly positive correlation with HGS/BMI in the control group (Figure 2, corrected).

**DISCUSSION**

The present study examined the association of HGS and BMI with cognitive function. HGS scores were significantly reduced in patients with schizophrenia compared to healthy controls. The HGS and BMI scores and the HGS/BMI were significantly associated with cognitive impairments in
### TABLE 1 | Demographic and clinical characteristics of the participants.

|                          | Patients with schizophrenia (n = 153) | Healthy controls (n = 328) | Statistical comparison |
|--------------------------|---------------------------------------|---------------------------|------------------------|
| **Age (years)**          | 36.9 ± 9.4 18-58                      | 36.4 ± 10.7 18-59         | \( t_{(334.7)} = -0.49, p = 0.63, \text{Cohen's } d = 0.05 \) |
| **Sex, male (%)**        | 82 (53.6)                                       | 150 (45.7)                         | \( \chi^2_{(1)} = 2.58, p = 0.11, \phi = -0.07 \) |
| **Education (years)**    | 14.0 ± 2.4 9-22                         | 15.1 ± 2.1 9-22              | \( t_{(267.1)} = 5.02, p = 9.4.E-07, \text{Cohen's } d = 0.51 \) |
| **Body mass index (kg/m²)** | 24.3 ± 5.1 14.3-45.2               | 22.1 ± 3.4 15.8-34.3         | \( t_{(209.5)} = -4.68, p = 5.0.E-06, \text{Cohen's } d = 0.54 \) |
| **Underweight**          | 15 (9.8)                                  | 26 (7.9)                       | \( \chi^2_{(1)} = 0.55, p = 0.46, \phi = 0.03 \) |
| **Normal**               | 85 (55.5)                                 | 43 (74.1)                      | \( \chi^2_{(1)} = 15.05, p = 1.0.E-04, \phi = -0.18 \) |
| **Overweight**           | 32 (20.9)                                | 47 (14.3)                      | \( \chi^2_{(1)} = 3.62, p = 0.057, \phi = 0.09 \) |
| **Obese**                | 17 (11.1)                                | 9 (2.7)                        | \( \chi^2_{(1)} = 14.71, p = 1.3.E-04, \phi = 0.18 \) |

**BACS**

- **Verbal memory** 40.6 ± 12.8 10-71
- **Working memory** 18.7 ± 4.5 8-28
- **Motor speed** 70.7 ± 16.4 22-100
- **Verbal fluency** 43.5 ± 12.3 14-76
- **Attention** 54.4 ± 13.3 19-86
- **Executive function** 16.7 ± 3.4 4-22
- **Composite** −1.00 ± 0.9 −3.89-1.01
- **Age of onset (years)** 23.1 ± 7.2 5-54
- **Duration of illness (years)** 13.7 ± 8.9 1-38

**CPeq (mg/day)**

- **Typical antipsychotics** 95.8 ± 220.7 0-1362.5
- **Atypical antipsychotics** 349.3 ± 375.7 0-1860
- **Total antipsychotics** 445.2 ± 410.3 0-1960

**Antiparkinson medication use (%)** 57 (37.3)

**Minor tranquilizer use (%)** 89 (58.2)

**Any psychotropic medication use (%)** 131 (85.6)

**PANSS**

- **Positive** 13.6 ± 5.0 7-32
- **Negative** 15.8 ± 6.1 7-33
- **General psychopathology** 29.9 ± 8.3 16-53

BACS, Brief Assessment of Cognition in Schizophrenia; CI, confidence interval; CPeq, chlorpromazine-equivalent dose; OR, odds ratio; PANSS, Positive and Negative Syndrome Scale. Significant p-values (p < 0.016 for the t-test, p < 0.01 for the chi-square test, and p < 0.007 for the multivariate analysis of covariance, corrected for multiple testing) are shown in bold exponents. There were 4 and 3 missing values of BMI scores in the patients and controls, respectively.

The HGS/BMI was significantly associated with only the BACS composite score in the control group. Our findings suggest that HGS and BMI have positive and negative relationships, respectively, with cognitive function in both male and female patients with schizophrenia. We found that patients with schizophrenia obtained lower HGS scores than in healthy controls, irrespective of sex or BMI. The HGS scores exhibited a positive correlation with the BACS motor speed, attention, and composite scores in the patient group. A previous study reported no correlation between HGS and cognitive scores measured by the psychosis evaluation tool for common use by caregivers [16]. In contrast, the current study demonstrates for the first time several correlations between HGS and cognitive measures using a comprehensive cognitive battery. Our results suggest a positive relationship between HGS and cognitive function in patients with schizophrenia under the age of 60 years. As reported with regard to elderly cognitive decline [4–7], HGS may be used as an additional index to reflect cognitive deficits in schizophrenia, particularly deficits of motor speed and attention.
attention. These deficits may be influenced by physical activity levels [14, 15].

BMI was negatively correlated with the BACS working memory, motor speed, and composite scores in the patient group. These correlations agree with prior findings [22, 23], and with our recent study reporting that obesity is associated with poorer cognitive function in patients with major depressive disorder [35]. Increased BMI in schizophrenia may be associated with lower physical activity levels [20, 23], although our data did not take physical activity into account. In addition, we observed a positive correlation between BMI and HGS scores in both the patient and control groups. These findings are in contrast with previous findings in patients with schizophrenia or schizoaffective disorder [24]. However, similar results to ours have been obtained in healthy controls [2, 36]. In addition, our BMI-based comparisons showed that higher and lower HGS scores were observed in obese and underweight participants, respectively. Taking the relationships of both HGS and BMI scores into consideration, the optimal BMI range (i.e., normal) may be beneficial for cognitive function in schizophrenia.

The ratio of HGS/BMI is a newly-defined index based on the former regression analyses. This ratio positively correlated with the BACS working memory, motor speed, verbal fluency, attention, and composite scores in the patient group. Furthermore, in bivariate correlation analyses, the ratio positively correlated with all BACS scores in the patients. These results suggest that the HGS/BMI could be a concise and useful index to estimate the level of cognitive performance in schizophrenia. In this context, higher HGS and lower BMI scores may contribute to the promotion of schizophrenic cognitive function. With regard to treatment, interventions for HGS and BMI using physical exercise have the potential to ameliorate cognitive dysfunctions in patients with schizophrenia. Such effects have previously been reported in cases of dementia [37, 38] and schizophrenia [39–42]. Considering the positive correlation between HGS and BMI scores, it is highly plausible that the balance of high HGS and low BMI scores, namely a higher HGS relative to BMI may be preferable for cognitive performance in schizophrenia.

Multiple regression analyses revealed that there were no effects of HGS on cognitive function, while the HGS/BMI was positively correlated with only the composite score in healthy controls. Notably, the HGS/BMI was positively associated with cognitive function in healthy controls, although the associations appeared to be weaker compared to patients with schizophrenia. Ceiling effects may contribute to the weaker association, as HGS and BACS scores were higher and BMI scores were lower in controls compared to patients. Moreover, specialized interactions between physical ability and cognitive function may be present in patients with schizophrenia, as suggested by previous studies [10–13]. Lifestyle factors observed in patients with schizophrenia [19], such as lower physical activity levels and higher BMI, may have influenced the difference between the patients and controls. Indeed, patients with schizophrenia were reported to be physically inactive compared to healthy controls [16], although data related to physical activity were not included in the present study.

This study had several limitations. First, the majority of the patients (85.7%) had taken psychotropic medications. These effects were accounted for by the ANCOVA and multiple regression analyses. Second, we conducted corrections for multiple testing using the Bonferroni method which may have resulted in type II errors due to the conservative nature of the analysis. Lastly, the cross-sectional approach of the current study cannot draw any conclusions concerning causal relationships. Given the correlational nature of the analysis, we cannot clarify whether cognitive dysfunction is the cause or result of low HGS in schizophrenia. It is possible that physical disabilities and cognitive deficits have individual and negative impacts on daily functioning in schizophrenia. This theory is supported by the therapeutic effects of aerobic exercise on brain structure and function via neuroplastic changes in patients with schizophrenia [43–46].

In conclusion, patients with schizophrenia showed lower HGS scores compared to healthy controls. In the patient group, HGS and BMI scores correlated positively and negatively with cognitive functions, respectively. Furthermore, the ratio of HGS/BMI positively correlated with the majority of the cognitive functions examined in the patient group. HGS/BMI may thus be a good index for cognitive performance in schizophrenia. These results suggest that a close relationship exists between physical status (muscle strength and BMI) and cognitive function in patients with schizophrenia.
### Table 3 | Multiple regression analysis for each sex involving Brief Assessment of Cognition in Schizophrenia (BACS) scores and forced-entry variables.

|                      | Verbal memory | Working memory | Motor speed | Verbal fluency | Attention | Executive function | Composite |
|----------------------|---------------|----------------|-------------|----------------|-----------|---------------------|-----------|
|                      | β             | p              | β           | p              | β         | p                   | β         | p               | β         | p         | β         | p         | β         | p         |
| ![Male patients](image)
| Handgrip strength (kg) | 0.15          | 0.21           | 0.16        | 0.19           | 0.29      | 0.01                | 0.23      | 0.05            | 0.47      | 4.0E-05   | 0.10      | 0.44      | 0.36      | 1.4E-03   |
| Age (years)          | -0.13         | 0.29           | -0.10       | 0.41           | 0.10      | 0.41                | 0.11      | 0.35            | -0.14     | 0.21      | 0.08      | 0.51      | -0.02     | 0.86      |
| Education (years)    | 0.15          | 0.22           | 0.15        | 0.23           | -0.04     | 0.72                | -0.05     | 0.68            | 0.08      | 0.48      | 0.02      | 0.87      | 0.08      | 0.47      |
| Body mass index (kg/m²) | -0.22         | 0.09           | -0.23       | 0.07           | -0.40     | 13.E-03             | -0.29     | 0.02            | -0.26     | 0.02      | -0.11     | 0.39      | -0.36     | 2.2E-03   |
| CPeq total antipsychotics (mg/day) | -0.11         | 0.36           | -0.05       | 0.67           | -0.19     | 0.12                | 0.01      | 0.91            | -0.07     | 0.50      | 0.10      | 0.42      | -0.07     | 0.50      |
| Any psychotropic medication use (%) | -0.09         | 0.48           | -0.11       | 0.40           | 0.09      | 0.47                | -0.34     | 5.9.E-03        | -0.14     | 0.20      | -0.26     | 0.05      | -0.21     | 0.06      |
| ![Female patients](image)
| Handgrip strength (kg) | 0.16          | 0.16           | 0.10        | 0.36           | 0.34      | 1.5E-03             | 0.25      | 0.04            | 0.36      | 1.4E-03   | 0.16      | 0.18      | 0.30      | 5.1E-03   |
| Age (years)          | -0.35         | 2.5.E-03       | -0.19       | 0.10           | 0.05      | 0.61                | -0.06     | 0.60            | -0.14     | 0.19      | -0.19     | 0.11      | -0.20     | 0.05      |
| Education (years)    | 0.26          | 0.03           | 0.17        | 0.16           | 0.21      | 0.05                | 0.25      | 0.04            | 0.14      | 0.21      | 0.00      | 0.98      | 0.22      | 0.04      |
| Body mass index (kg/m²) | -0.16         | 0.17           | -0.34       | 6.9.E-03       | -0.15     | 0.18                | -0.25     | 0.05            | -0.29     | 0.01      | -0.05     | 0.69      | -0.26     | 0.02      |
| CPeq total antipsychotics (mg/day) | -0.09         | 0.45           | -0.17       | 0.18           | -0.17     | 0.14                | 0.02      | 0.89            | -0.22     | 0.07      | -0.37     | 6.9.E-03   | -0.23     | 0.05      |
| Any psychotropic medication use (%) | -0.11         | 0.38           | -0.05       | 0.73           | -0.32     | 0.01                | -0.06     | 0.68            | -0.06     | 0.65      | -0.03     | 0.82      | -0.14     | 0.25      |
| ![Male controls](image)
| Handgrip strength (kg) | 0.01          | 0.89           | 0.01        | 0.89           | 0.03      | 0.70                | -0.01     | 0.89            | -0.01     | 0.93      | 0.12      | 0.14      | 0.04      | 0.63      |
| Age (years)          | -0.46         | 3.9.E-08       | -0.46       | 3.9.E-08       | -0.23     | 0.01                | -0.06     | 0.48            | -0.49     | 1.0.E-09   | -0.16     | 0.08      | -0.36     | 6.4.E-06   |
| Education (years)    | -0.11         | 0.16           | 0.03        | 0.72           | 0.19      | 0.01                | 0.24      | 3.5.E-03        | 0.16      | 0.02      | 0.13      | 0.11      | 0.27      | 2.9.E-04   |
| Body mass index (kg/m²) | 0.03          | 0.72           | -0.11       | 0.16           | -0.16     | 0.07                | -0.08     | 0.37            | -0.09     | 0.23      | -0.03     | 0.71      | -0.15     | 0.06      |
| ![Female controls](image)
| Handgrip strength (kg) | 0.04          | 0.60           | 0.04        | 0.58           | 0.07      | 0.39                | 0.14      | 0.06            | 0.15      | 0.04      | 0.06      | 0.46      | 0.14      | 0.06      |
| Age (years)          | -0.23         | 4.8.E-03       | -0.10       | 0.23           | 0.00      | 0.97                | 0.10      | 0.25            | -0.20     | 0.01      | -0.02     | 0.77      | -0.12     | 0.11      |
| Education (years)    | 0.17          | 0.04           | 0.14        | 0.08           | 0.01      | 0.88                | 0.27      | 9.3.E-04        | 0.24      | 2.2.E-03   | 0.23      | 5.4.E-03   | 0.29      | 1.5.E-04   |
| Body mass index (kg/m²) | -0.06         | 0.44           | -0.21       | 5.8.E-03       | -0.15     | 0.06                | -0.12     | 0.11            | -0.17     | 0.02      | -0.07     | 0.38      | -0.22     | 2.8.E-03   |

CPeq, chlorpromazine-equivalent dose. Significant p-values (p < 0.007; corrected for multiple testing) are shown in bold exponents.
### TABLE 4 | Multiple regression analysis between Brief Assessment of Cognition in Schizophrenia (BACS) scores and handgrip strength/body mass index.

|                  | Verbal memory | Working memory | Motor speed | Verbal fluency | Attention | Executive function | Composite |
|------------------|---------------|----------------|-------------|----------------|-----------|---------------------|-----------|
|                  | β  | p    | β  | p    | β  | p    | β  | p    | β  | p    | β  | p    | β  | p    | β  | p    | β  | p    |
| **Patients with schizophrenia** | R² = 0.19 | R² = 0.19 | R² = 0.23 | R² = 0.15 | R² = 0.32 | R² = 0.09 | R² = 0.35 |
| Handgrip strength/body mass index (m²) | 0.26 | 0.01 | 0.35 | 9.7E-04 | 0.47 | 1.2E-05 | 0.40 | 2.3E-04 | 0.56 | 2.9E-08 | 0.15 | 0.17 | 0.51 | 1.8E-07 |
| Age (years) | −0.26 | 1.7E-03 | −0.14 | 0.08 | 0.06 | 0.47 | 0.01 | 0.91 | −0.14 | 0.06 | −0.07 | 0.39 | −0.13 | 0.08 |
| Sex | 0.19 | 0.07 | 0.06 | 0.53 | 0.38 | 2.0E-04 | 0.21 | 0.05 | 0.37 | 9.4E-05 | −0.11 | 0.29 | 0.26 | 4.6E-03 |
| Education (years) | 0.22 | 0.01 | 0.17 | 0.04 | 0.07 | 0.36 | 0.10 | 0.21 | 0.12 | 0.12 | 0.04 | 0.65 | 0.17 | 0.02 |
| CPeq total antipsychotics (mg/day) | −0.10 | 0.24 | −0.08 | 0.33 | −0.17 | 0.04 | 0.01 | 0.91 | −0.13 | 0.10 | −0.10 | 0.27 | −0.13 | 0.09 |
| Any psychotropic medication use (%) | −0.10 | 0.25 | −0.10 | 0.25 | −0.09 | 0.30 | −0.18 | 0.04 | −0.07 | 0.37 | −0.15 | 0.10 | −0.16 | 0.04 |
| **Healthy controls** | R² = 0.19 | R² = 0.09 | R² = 0.02 | R² = 0.08 | R² = 0.25 | R² = 0.06 | R² = 0.22 |
| Handgrip strength/body mass index (m²) | 0.10 | 0.15 | 0.14 | 0.04 | 0.10 | 0.19 | 0.13 | 0.08 | 0.17 | 0.01 | 0.12 | 0.10 | 0.20 | 2.6E-03 |
| Age (years) | −0.37 | 5.7E-12 | −0.20 | 3.7E-04 | 0.00 | 0.98 | 0.00 | 0.93 | −0.37 | 9.8E-13 | −0.09 | 0.12 | −0.28 | 1.3E-07 |
| Sex | 0.25 | 2.3E-04 | 0.07 | 0.35 | 0.10 | 0.19 | 0.24 | 1.1E-03 | 0.27 | 4.5E-05 | 0.02 | 0.78 | 0.25 | 1.7E-04 |
| Education (years) | 0.08 | 0.12 | 0.16 | 4.8E-03 | 0.15 | 0.01 | 0.25 | 1.2E-05 | 0.18 | 3.1E-04 | 0.18 | 1.6E-03 | 0.27 | 3.7E-07 |

CPe, chlorpromazine-equivalent dose. Significant p-values (p < 0.0071; corrected for multiple testing) are shown in bold exponents. Sex was coded as male: 1 and female: 2.
FIGURE 1 | Scatter plots of correlations between handgrip strength (HGS)/body mass index (BMI) and Brief Assessment of Cognition in Schizophrenia (BACS) scores in patients with schizophrenia. HGS/BMI positively correlated with all of the BACS scores (A–G) in the patients with schizophrenia (all \( p < 0.0071 \), corrected for multiple testing). Black and white circles indicate male and female patients, respectively. Significant \( p \)-values are shown in exponents. \( r \), Pearson’s correlation coefficient.
FIGURE 2 | Scatter plots of correlations between handgrip strength (HGS) and body mass index (BMI) and Brief Assessment of Cognition in Schizophrenia (BACS) scores in healthy controls. HGS/BMI positively correlated with only the BACS working memory score (B, not A or C–G) in the controls ($p < 0.0071$, corrected for multiple testing). Black and white squares indicate male and female controls, respectively. A significant $p$-value is shown in an exponent. $r$, Pearson's correlation coefficient.
AUTHORS CONTRIBUTIONS

SH designed, and HK supervised the study; JM, II, and MH assessed cognitive function by the BACS, SH, TT, MO, and KH determined psychiatric diagnoses and evaluated symptoms by the Positive and Negative Syndrome Scale; SH performed the statistical analysis and wrote the draft of the manuscript. All authors have approved the final manuscript.

FUNDING

This study was supported by Intramural Research Grants (24-11, 27-1, and 27-6) for Neurological and Psychiatric Disorders at National Center of Neurology and Psychiatry (HK) and Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and development, AMED (HK). These funding sources were involved only in the financial support.

ACKNOWLEDGMENTS

This paper was proofread by a scientific editor at Editage, Tokyo, Japan.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2018.00156/full#supplementary-material

REFERENCES

1. Luna-Heredia E, Martin-Pena G, Ruiz-Galiana J. Handgrip dynamometry in healthy adults. Clin Nutr. (2005) 24:250–8. doi: 10.1016/j.clnu.2004.10.007
2. Budziareck MB, Pureza Duarte RR, Barbosa-Silva MC. Reference values and determinants for handgrip strength in healthy subjects. Clin Nutr. (2008) 27:357–62. doi: 10.1016/j.clnu.2008.03.008
3. De Lima TR, Silva DAS, De Castro JAC, Christofaro DGD. Handgrip strength and associated sociodemographic and lifestyle factors: a systematic review of the adult population. J Bodyw Mov Ther. (2017) 21:401–13. doi: 10.1016/j.jbmt.2016.08.017
4. Cooper R, Kuh D, Cooper G, Gale CR, Lawlor DA, Matthews F, et al. Objective measures of physical capability and subsequent health: a systematic review. Age Ageing (2011) 40:14–23. doi: 10.1093/ageing/afl117
5. Cloutson SA, Brewster P, Kuh D, Richards M, Cooper R, Hardy R, et al. The dynamic relationship between physical function and cognition in longitudinal aging cohorts. Epidemiol Rev. (2013) 35:33–50. doi: 10.1093/epirev/mxs004
6. Rijkm JM, Roos PR, Deckx L, van den Akker M, Buntinx F. Prognostic value of actigraphy-derived physical activity and cognitive performance and disability in schizophrenia. Schizophr Res Cogn. (2016) 12:3161–72. doi: 10.1016/bbph.13772
7. Firth J, Cotter J, Carney R, Yung AR. The pro-cognitive mechanisms of physical exercise in people with schizophrenia. Br J Pharmacol. (2017) 174:1361–72. doi: 10.1111/bjph.13772
8. Chen LJ, Steptoe A, Chung MS, Ku PW. Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia. Psychol Med. (2016) 46:2375–84. doi: 10.1017/S0033291716009921
9. Harvey PD, Rosenthal JB. Cognitive and functional deficits in people with schizophrenia. Schizophr Res. (2012) 143:451–67. doi: 10.1016/j.schres.2012.03.046
10. Vancampfort D, Probst M, Scheewe T, De Herdt A, Sweers K, Knaep J, et al. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. (2013) Psychiatry Res. 207:25–32. doi: 10.1016/j.psychres.2012.09.026
11. Hustall FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today (2015) 50:117–28. doi: 10.1097/NT.0000000000000092
12. Van Dyck C, Cerin E, De Bourdeaudhuij I, Hinckson E, Reis RS, Davrey R, et al. International study of objectively measured physical activity and sedentary time with body mass index and obesity: IPEN adult study. Int J Obes. (2015) 39, 199–207. doi: 10.1038/ijo.2014.115
13. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. (2015) 132:97–108. doi: 10.1111/acps.12445
14. Vancampfort D, Probst M, Knaep J, Carraro A, and De Hert M. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. (2012a) 200:73–8. doi: 10.1016/j.psychres.2012.03.046
15. Smethen GA, Mccormick BP, Lysaker P. Physical activity and psychiatric symptoms in adults with schizophrenia spectrum disorders. J Nerv Ment Dis. (2014) 202:845–52. doi: 10.1097/NMD.0000000000000216
16. Vancampfort D, Probst M, Scheewe T, De Herdt A, Sweers K, Knaep J, et al. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. (2013) Psychiatry Res. 207:25–32. doi: 10.1016/j.psychres.2012.09.026
17. Nuttall FQ, Body mass index: obesity, BMI, and health: a critical review. Nutr Today (2015) 50:117–28. doi: 10.1097/NT.0000000000000092
18. Van Dyck C, Cerin E, De Bourdeaudhuij I, Hinckson E, Reis RS, Davrey R, et al. International study of objectively measured physical activity and sedentary time with body mass index and obesity: IPEN adult study. Int J Obes. (2015) 39, 199–207. doi: 10.1038/ijo.2014.115
19. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. (2015) 132:97–108. doi: 10.1111/acps.12445
20. Vancampfort D, Probst M, Knaep J, Carraro A, and De Hert M. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. (2012a) 200:73–8. doi: 10.1016/j.psychres.2012.03.046
21. Soundy A, Roskell C, Stubbs B, Probst M, Vancampfort D. Investigating the benefits of sport participation for individuals with schizophrenia: a systematic review. Psychiar Danub. (2015) 27:2–13.
22. Guo X, Zhang Z, Wei Q, Li H, Wu R, Zhao J. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry (2013) 13:109. doi: 10.1186/1471-244X-13-109
23. Kimbhy D, Vakhрушева J, Bartels MN, Armstrong HF, Ballon JS, Khan S, et al. Aerobic fitness and body mass index in individuals with schizophrenia: implications for neurocognition and daily functioning. Psychiatry Res. (2014) 220:784–91. doi: 10.1016/j.psychres.2014.08.052
24. Vancampfort D, Probst M, Sweers K, Maurissen K, Knaep J, Willems JB, et al. Eurofit test battery in patients with schizophrenia or schizoaffective disorder: reliability and clinical correlates. Eur Psychiatry (2012b) 27:416–21. doi: 10.1016/j.eurpsy.2011.01.009
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59(Suppl. 20), 22–33; quiz 34–57.
26. Otsuob T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et al. Reliability and validity of Japanese version of the Mini-International Neuropsychiatric Interview. Psychiatry Clin Neurosci. (2005) 59:517–26. doi: 10.1111/j.1440-1819.2005.01408.x
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association (1994).
28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA (2013) 310:2191–4. doi:10.1001/jama.2013.281053
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. (1987) 13:261–76. doi:10.1093/schbul/13.2.261
30. Igarashi Y, Hayashi N, Yamashina M, Otsuka N, Kuroki N, Anzai N, et al. Interrater reliability of the Japanese version of the Positive and Negative Syndrome Scale and the appraisal of its training effect. Psychiatry Clin Neurosci. (1998) 52:467–70. doi:10.1046/j.1440-1819.1998.00425.x
31. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. (2004) 68:283–97. doi:10.1016/j.schres.2003.09.011
32. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. (2007) 61:602–9. doi:10.1111/j.1440-1819.2007.01725.x
33. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. (2015) 69:440–7. doi:10.1111/pcn.12275
34. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. (2000) 894:1–xii, 1–253.
35. Hidese S, Ota M, Matsuo J, Ishida I, Hiraishi M, Yoshida S, et al. Association of obesity with cognitive function and brain structure in patients with major depressive disorder. J Affect Disord. (2018) 225:188–94. doi:10.1016/j.jad.2017.08.028
36. Alahmari KA, Silvian SP, Reddy RS, Kakaraparthi VN, Ahmad I, Alam MM. Hand grip strength determination for healthy males in Saudi Arabia: a study of the relationship with age, body mass index, hand length and forearm circumference using a hand-held dynamometer. J Int Med Res. (2017) 45:540–8. doi:10.1177/0300060516688976
37. Bernardo TC, Marques-Aleixo I, Beleza J, Oliveira PJ, Ascensao A, Magalhaes J. Physical exercise and brain mitochondrial fitness: the possible role against Alzheimer’s disease. Brain Pathol. (2016) 26:648–63. doi:10.1111/bpa.12403
38. Koscak Tivadar B. Physical activity improves cognition: possible explanations. Biogerontology (2017) 18:477–83. doi:10.1007/s10522-017-9708-6
39. Kimhy D, Vakhrusheva J, Bartels MN, Armstrong HF, Ballon JS, Khan S, et al. The Impact of aerobic exercise on brain-derived neurotrophic factor and neurocognition in individuals with schizophrenia: a single-blind, randomized clinical trial. Schizophr Bull. (2015) 41:859–68. doi:10.1093/schbul/sbv022
40. Kimhy D, Lauriola V, Bartels MN, Armstrong HF, Vakhrusheva J, Ballon JS, et al. Aerobic exercise for cognitive deficits in schizophrenia - the impact of frequency, duration, and fidelity with target training intensity. Schizophr Res. (2016) 172:213–3. doi:10.1016/j.schres.2016.01.055
41. Nuechterlein KH, Ventura J, Mcewen SC, Gretchen-Doorly D, Vinogradov S, Subotnik KL. Enhancing cognitive training through aerobic exercise after a first schizophrenia episode: theoretical conception and pilot study. Schizophr Bull. (2016) 42(Suppl. 1):S44–S52. doi:10.1093/schbul/sbw007
42. Su CY, Wang PW, Lin YJ, Tang TC, Liu MF, Chen MD. The effects of aerobic exercise on cognition in schizophrenia: a 3-month follow-up study. Psychiatry Res. (2016) 244:394–402. doi:10.1016/j.psychres.2016.08.011
43. Kandola A, Hendriks J, Lucassen PJ, Yucel M. Aerobic exercise as a tool to improve hippocampal plasticity and function in humans: practical implications for mental health treatment. Front Hum Neurosci. (2016) 10:373. doi:10.3389/fnhum.2016.00373
44. Vakhrusheva J, Marino B, Stroup TS, Kimhy D. Aerobic exercise in people with schizophrenia: neural and neurocognitive benefits. Curr Behav Neurosci Rep. (2016) 3:165–75. doi:10.1007/s40473-016-0077-2
45. Campos C, Rocha NBF, Lattari E, Nardi AE, Machado S. Exercise induced neuroplasticity to enhance therapeutic outcomes of cognitive remediation in schizophrenia: analyzing the Role of Brain Derived Neurotrophic Factor. CNS Neurol Disord Drug Targets (2017) 16:638–51. doi:10.2174/1871527315666161223142918
46. Falkai P, Malchow B, Schmitt A. Aerobic exercise and its effects on cognition in schizophrenia. Curr Opin Psychiatry (2017) 30:171–5. doi:10.1097/YCO.0000000000000326

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Hidese, Matsuo, Ishida, Hiraishi, Teraishi, Ota, Hattori and Kunugi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.